Epstein Barr Virus Infection in Patients With Radiologically Isolated Syndrome (EBV-RIS)
Prevalence and Prognostic Value of Epstein Barr Virus (EBV) Infection in Patients With Radiologically Isolated Syndrome (RIS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: christine LEBRUN-FRENAY
- Phone Number: 0492038528
- Email: lebrun-frenay.c@chu-nice.fr
Study Contact Backup
- Name: Cassandre Landes-Chateau
- Phone Number: 0492034126
- Email: landes.c@chu-nice.fr
Study Locations
-
-
-
Nice, France, 06000
- Nice University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients with RIS confirmed by the RIS expert center of the Nice CHU; EBNA status at RIS diagnosis available
Exclusion Criteria:
none
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
RIS Patient
RIS patients validated by the RIS expert group
|
NO INTERVENTION
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparaison of IgG EBNA status at RIS diagnostic in patients who remain RIS and those who develop MS according to their conversion delay
Time Frame: Retrospectively at baseline (RIS diagnosis)
|
IgG EBNA (negative/positive)
|
Retrospectively at baseline (RIS diagnosis)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparaison of IgM VCA EBNA status at RIS diagnostic in patients who remain RIS and those who develop MS according to their conversion delay
Time Frame: Retrospectively at baseline (RIS diagnosis) and through study completion, an average of 5 years.
|
quantity of IgM VCA EBNA (U/ml)
|
Retrospectively at baseline (RIS diagnosis) and through study completion, an average of 5 years.
|
|
Comparaison of IgG VCA EBNA status at RIS diagnostic in patients who remain RIS and those who develop MS according to their conversion delay
Time Frame: Retrospectively at baseline (RIS diagnosis) and through study completion, an average of 5 years.
|
quantity of IgM VCA EBNA (U/ml)
|
Retrospectively at baseline (RIS diagnosis) and through study completion, an average of 5 years.
|
|
Prevalence of EBV seropositivity in RIS patients according to their MRI activity
Time Frame: Retrospectively at baseline (RIS diagnosis) and through study completion, an average of 5 years.
|
EBV seropositivity (negative/positive) according clinical event and Dissemination in time and in space
|
Retrospectively at baseline (RIS diagnosis) and through study completion, an average of 5 years.
|
|
Prevalence of EBV seropositivity in RIS patients according to their clinical and/or MRI activity (EDA)
Time Frame: Retrospectively at baseline (RIS diagnosis) and through study completion, an average of 5 years.
|
EBV seropositivity (negative/positive) according clinical event and Dissemination in time and in space
|
Retrospectively at baseline (RIS diagnosis) and through study completion, an average of 5 years.
|
|
Assessment correlation between antibodies titers and clinical conversion
Time Frame: Retrospectively at baseline (RIS diagnosis) and through study completion, an average of 5 years.
|
quantity of IgG VCA EBNA (U/ml) and IgM VCA EBNA (U/ml) according Dissemination in time and in space
|
Retrospectively at baseline (RIS diagnosis) and through study completion, an average of 5 years.
|
|
Assessment correlation between antibodies titers and clinical and/or MRI activity (EDA)
Time Frame: Retrospectively at baseline (RIS diagnosis) and through study completion, an average of 5 years.
|
quantity of IgG VCA EBNA (U/ml) and quantity of IgM VCA EBNA (U/ml) according clinical event and Dissemination in time and in space
|
Retrospectively at baseline (RIS diagnosis) and through study completion, an average of 5 years.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Pathologic Processes
- Autoimmune Diseases
- Immune System Diseases
- Infections
- Virus Diseases
- Disease
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- DNA Virus Infections
- Herpesviridae Infections
- Tumor Virus Infections
- Syndrome
- Multiple Sclerosis
- Epstein-Barr Virus Infections
Other Study ID Numbers
Other Study ID Numbers
- 23Neuro01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.